Leerink Partnrs Analysts Raise Earnings Estimates for AxoGen

AxoGen, Inc. (NASDAQ:AXGN) – Leerink Partnrs upped their FY2024 earnings estimates for shares of AxoGen in a research note issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now anticipates that the medical equipment provider will earn ($0.31) per share for the year, up from their prior forecast of ($0.32). The consensus estimate for AxoGen’s current full-year earnings is ($0.30) per share. Leerink Partnrs also issued estimates for AxoGen’s Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.06) EPS, FY2026 earnings at $0.17 EPS, FY2027 earnings at $0.26 EPS and FY2028 earnings at $0.34 EPS.

Other equities analysts have also issued research reports about the stock. StockNews.com upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. JMP Securities increased their target price on AxoGen from $17.00 to $20.00 and gave the stock a “market outperform” rating in a research report on Friday, August 9th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, AxoGen currently has an average rating of “Buy” and a consensus target price of $15.00.

AxoGen Price Performance

AxoGen stock opened at $13.61 on Wednesday. AxoGen has a 1 year low of $5.55 and a 1 year high of $15.90. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. The firm has a 50 day moving average price of $13.73 and a 200 day moving average price of $10.68.

Institutional Trading of AxoGen

Large investors have recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. grew its stake in shares of AxoGen by 2,014.6% in the second quarter. Assenagon Asset Management S.A. now owns 1,310,811 shares of the medical equipment provider’s stock valued at $9,490,000 after buying an additional 1,248,823 shares in the last quarter. Divisadero Street Capital Management LP grew its position in AxoGen by 587.2% in the second quarter. Divisadero Street Capital Management LP now owns 686,994 shares of the medical equipment provider’s stock valued at $4,974,000 after acquiring an additional 587,024 shares in the last quarter. Rice Hall James & Associates LLC raised its stake in shares of AxoGen by 26.8% during the second quarter. Rice Hall James & Associates LLC now owns 194,269 shares of the medical equipment provider’s stock valued at $1,407,000 after purchasing an additional 41,095 shares during the period. Semanteon Capital Management LP acquired a new position in shares of AxoGen during the third quarter worth $603,000. Finally, Creative Planning grew its holdings in AxoGen by 152.2% during the 3rd quarter. Creative Planning now owns 29,790 shares of the medical equipment provider’s stock valued at $418,000 after purchasing an additional 17,980 shares in the last quarter. 80.29% of the stock is currently owned by institutional investors and hedge funds.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.